Volume 21 Issue 11
Nov.  2023
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2023  >  21(11): 1876-1879
XIA Yi, LI Xuelong, QIAO Fengjie, DONG Wenbin. The effect of Shexiang Baoxin Pills combined with recombinant human brain natriuretic peptide in the treatment of ischemic heart failure[J]. Chinese Journal of General Practice, 2023, 21(11): 1876-1879. doi: 10.16766/j.cnki.issn.1674-4152.003247
Citation: XIA Yi, LI Xuelong, QIAO Fengjie, DONG Wenbin. The effect of Shexiang Baoxin Pills combined with recombinant human brain natriuretic peptide in the treatment of ischemic heart failure[J]. Chinese Journal of General Practice, 2023, 21(11): 1876-1879. doi: 10.16766/j.cnki.issn.1674-4152.003247
shu

The effect of Shexiang Baoxin Pills combined with recombinant human brain natriuretic peptide in the treatment of ischemic heart failure

doi: 10.16766/j.cnki.issn.1674-4152.003247

  • Department of Cardiology, Fuyang District Hospital of Traditional Chinese Medicine, Hangzhou, Zhejiang 311400, China

Funds:

 2023XY022

 B20220321

  • Received Date: 2023-05-24
    Available Online: 2024-01-13
    Abstract
  •   Objective  To explore the clinical efficacy of Shexiang Baoxin pills combined with recombinant human brain natriuretic peptide in the treatment of ischemic heart failure, in order to provide reference for the treatment of ischemic heart failure patients.  Methods  A total of 100 patients with ischemic heart failure admitted to Fuyang District Hospital of Traditional Chinese Medicine in Hangzhou from January 2022 to January 2023 were selected as study subjects and randomly divided into two groups by random number table method. Patients in control group (n=50) received recombinant human brain natriuretic peptide therapy on the basis of conventional treatment, and patients in observation group (n=50) received combined therapy with Shexiang Baoxin Pills on the basis of control group. The overall response rate, pre-and post-treatment cardiac function (left ventricular ejection fraction, left ventricular end-diastolic diameter and left ventricular end-systolic diameter), traditional Chinese medicine (TCM) syndrome score and adverse drug reactions were compared in both groups.  Results  Compared with the control group, left ventricular Ejection fraction was significantly increased in the observation group [(50.25±5.64)% vs. (45.58±5.47)%, t=4.203, P < 0.001], the left ventricular end diastolic diameter [(52.64±4.44) mm vs. (55.38±4.07) mm, t=3.217, P=0.002], left ventricular end systolic diameter [(38.21±4.16) mm vs. (42.38±4.58) mm, t=4.766, P < 0.001], and the TCM syndrome score was significantly reduced [(8.39±2.66) points vs. (11.67±2.95) points, t=5.839, P < 0.001]; The overall effect of TCM syndrome in the observation group was better than that in the control group (Z=-2.289, P=0.022). There were no significant differences in the overall efficacy rate and the incidence of adverse reactions between the two groups (all P>0.05).  Conclusion  The combined use of Shexiang Baoxin Pills and recombinant human brain natriuretic peptide on the basis of conventional heart failure treatment can significantly improve the clinical efficacy and cardiac function of patients with ischemic heart failure, which is superior to the use of recombinant human brain natriuretic peptide alone.

     

    • FullText(HTML)
  • loading
    • References(20)
  • [1]
    李柏红, 施恒荷, 刘斌. 新型抗心力衰竭药物的研究进展[J]. 中国医药, 2021, 16(1): 142-144.

    LI B H, SHI H H, LIU B. Research progress of novel anti-heart failure drugs[J]. China Medicine, 2021, 16(1): 142-144.
    [2]
    叶明, 王鑫, 孙悦, 等. 芪苈强心胶囊联合重组人脑利钠肽对急性心力衰竭患者的临床疗效观察[J]. 中华内科杂志, 2023, 62(4): 422-426.

    YE M, WANG X, SUN Y, et al. Clinical effect of Qiliqiangxin capsule combined with recombinant human brain natriuretic peptide on patients with acute heart failure[J]. Chinese Journal of Internal Medicine, 2023, 62(4): 422-426.
    [3]
    崔建国, 梁淑芹, 齐洁, 等. 小剂量联合重组人脑利钠肽和沙库巴曲缬沙坦治疗老年急性心力衰竭的短期疗效[J]. 实用医学杂志, 2020, 36(21): 2984-2989. doi: 10.3969/j.issn.1006-5725.2020.21.020

    CUI J G, LIANG S Q, QI J, et al. Short-term efficacy of low dose combined with recombinant human brain natriuretic peptide and sackubatrol valsartan in the treatment of acute heart failure in elderly patients[J]. The Journal of Practical Medicine, 2020, 36(21): 2984-2989. doi: 10.3969/j.issn.1006-5725.2020.21.020
    [4]
    BURCH G E, TSUI C Y, HARB J M. Ischemic cardiomyopathy[J]. Am Heart J, 1972, 83(3): 340-350. doi: 10.1016/0002-8703(72)90435-8
    [5]
    YANCY C W, JESSUP M, BOZKURT B, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines[J]. Circulation, 2013, 128(16): 1810-1852. doi: 10.1161/CIR.0b013e31829e8807
    [6]
    中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会, 中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志, 2018, 46(10): 760-789. doi: 10.3760/cma.j.issn.0253-3758.2018.10.004

    Heart failure Group, Chinese Society of Cardiology, Heart Failure Professional Committee, Chinese Medical Doctor Association, Editorial Committee of Chinese Journal of Cardiology. Chinese guidelines for diagnosis and treatment of heart failure 2018[J]. Chinese Journal of Cardiolog, 2018, 46(10): 760-789. doi: 10.3760/cma.j.issn.0253-3758.2018.10.004
    [7]
    郑筱萸. 中药新药临床研究指导原则[S]. 北京: 中国医药科技出版社, 2002: 253-258.

    ZHENG X Y. Guiding principles for clinical research of new Chinese medicine[S]. Beijing: China Medical Science and Technology Press, 2002: 253-258.
    [8]
    林果为, 王吉耀, 葛均波. 实用内科学[M]. 北京: 人民卫生出版社, 2017.

    LIN G W, WANG J Y, GE J B. Practical Internal Medicine[M]. Beijing: People's Medical Publishing House, 2017.
    [9]
    MEHRA M R, VADUGANATHAN M, FU M, et al. A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial[J]. Eur Heart J, 2019, 40(44): 3593-3602. doi: 10.1093/eurheartj/ehz427
    [10]
    许顶立. 应重视心力衰竭的临床新分类和药物治疗新策略[J]. 中华心血管病杂志, 2023, 51(4): 335-337.

    XU D L. Clinical value of the new clinical classification and medical treatment strategy of heart failure[J]. Chinese Journal of Cardiology, 2023, 51(4): 335-337.
    [11]
    靳海斌. 慢性心力衰竭的神经调节治疗及沙库巴曲缬沙坦钠应用新进展[J]. 心血管病学进展, 2019, 40(2): 283-286.

    JIN H B. Recent progress in neuromodulation therapy of chronic heart failure and application of sackubactril valsartan sodium[J]. Advances in Cardiovascular Diseases, 2019, 40(2): 283-286.
    [12]
    刘敏, 王秋林. 重组人脑利钠肽在心血管病中的应用研究进展[J]. 成都医学院学报, 2020, 15(5): 673-676.

    LIU M, WANG Q L. Research progress on application of recombinant human brain natriuretic peptide in cardiovascular disease[J]. Journal of Chengdu Medical College, 2019, 15(5): 673-676.
    [13]
    曾繁宇, 文子尹, 叶文捷. 重组人脑利钠肽对急性重症心力衰竭患者的治疗效果及预后的影响[J]. 临床医学工程, 2019, 26(5): 635-636.

    ZENG F Y, WEN Z Y, YE W J. Effect of recombinant human brain natriuretic peptide on treatment and prognosis of patients with acute severe heart failure[J]. Clinical Medical & Engineering, 2019, 26(5): 635-636.
    [14]
    丁文虹, 崔胜男, 扈春丽, 等. 冻干重组人脑利钠肽联合米力农治疗老年慢性肺心病合并心力衰竭的临床疗效[J]. 中国老年学杂志, 2022, 42(6): 1295-1298.

    DING W H, CUI S N, HU C L, et al. Clinical effect of freeze-dried recombinant human brain natriuretic peptide combined with Milrinone in treatment of chronic pulmonary heart disease complicated with heart failure in elderly patients[J]. Chinese Journal of Gerontology, 2022, 42(6): 1295-1298.
    [15]
    孙莉, 荀平. 重组人脑利钠肽对慢性心衰急性发作期患者的用药不良反应发生率及疗效分析[J]. 中西医结合心血管病电子杂志, 2020, 8(31): 50, 54.

    SUN L, XUN P. Incidence and efficacy of recombinant human brain natriuretic peptide in patients with chronic heart failure at acute stage of adverse drug reactions[J]. Cardiovascular Disease Journal of Integrated Traditional Chinese and Western Medicine(Electronic), 2020, 8(31): 50, 54.
    [16]
    姚久秀, 戴国华. 中医药干预慢性心力衰竭系统评价的研究进展[J]. 中医药学报, 2021, 49(4): 84-87.

    YAO J X, DAI G H. Research progress of systematic evaluation of Chinese medicine intervention in chronic heart failure[J]. Acta Chinese Medicine and Pharmacology, 2021, 49(4): 84-87.
    [17]
    尹红伟, 王慈, 王帅, 等. 心力衰竭发生发展的自噬机制及中医药干预研究进展[J]. 天津中医药大学学报, 2021, 40(6): 685-690.

    YIN H W, WANG C, WANG S, et al. Research progress of autophagy mechanism in the occurrence and development of heart failure and TCM intervention[J]. Journal of Tianjin University of Traditional Chinese Medicine, 2021, 40(6): 685-690.
    [18]
    张芳, 陈国藩, 任开涵, 等. 麝香保心丸对老年慢性心力衰竭患者心功能、心室重构及血管内皮因子的影响[J]. 中华全科医学, 2022, 20(12): 2006-2009. doi: 10.16766/j.cnki.issn.1674-4152.002756

    ZHANG F, CHEN G F, REN K H, et al. Effects of Shexiang Baoxin Pills on cardiac function, ventricular remodeling and vascular endothelial factors in elderly patients with chronic heart failure[J]. Chinese Journal of General Practice, 2022, 20(12): 2006-2009. doi: 10.16766/j.cnki.issn.1674-4152.002756
    [19]
    廖丛娟, 张旭升, 黄战军, 等. 麝香保心丸下调代谢综合征大鼠心肌组织尾加压素Ⅱ及其受体表达的实验研究[J]. 中西医结合心脑血管病杂志, 2020, 18(15): 2414-2417.

    LIAO C J, ZHANG X S, HUANG Z J, et al. Effect of Shexiang Baoxin Pill on the expression of tail vasopressin Ⅱ and its receptor in myocardial tissue of rats with metabolic syndrome[J]. Chinese Journal of Integrative Medicine on Cardio/Cerebrovascular Disease, 2020, 18(15): 2414-2417.
    [20]
    高天辉, 陈志鸿. 麝香保心丸辅助治疗稳定性冠心病的疗效观察[J]. 中西医结合心脑血管病杂志, 2021, 19(21): 3807-3808.

    GAO T H, CHEN Z H. Observation on the curative effect of Shexiang Baoxin Pill in the treatment of stable coronary heart disease[J]. Chinese Journal of Integrative Medicine on Cardio/Cerebrovascular Disease, 2021, 19(21): 3807-3808.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (177) PDF downloads(12) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return